University of South Florida (GVAX vaccine) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
University of South Florida (GVAX vaccine) General Information
Description
CD40LGVAX vaccine to resist lung cancer. The asset includes irradiated allogeneic lung adenocarcinoma cells which are combined with a bystander cell line transfected with hCD40L and hGM-CSF.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Biotechnology
Acquirer
Primary Office
- CA
- United States
University of South Florida (GVAX vaccine) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
University of South Florida (GVAX vaccine) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|